Analysts Bullish as Ventyx Biosciences (VTYX) Advances Its Clinical and Strategic Initiatives

Core Viewpoint - Ventyx Biosciences, Inc. (NASDAQ:VTYX) is recognized as one of the 12 best multibagger stocks to buy heading into 2026 due to strong 1-year returns and significant upside potential [1] Group 1: Analyst Sentiment and Price Target - As of December 18, 2025, 90% of analysts are bullish on Ventyx Biosciences, setting a median price target of $14.00, indicating an upside potential of 82.05% [2] Group 2: Strategic and Clinical Developments - On December 2, 2025, Ventyx announced the addition of Mark McKenna as Strategic Advisor and Dr. Peter Libby as Clinical Advisor, enhancing its advisory board [3] - The company reported progress in its ongoing phase 2 study of VTX2735 for recurrent pericarditis, with the expanded advisory team expected to facilitate key decisions for both VTX2735 and VTX3232, which has already shown positive Phase 2 data [4] Group 3: Revised Guidance and Study Focus - Ventyx revised its guidance for the interim analysis of the Phase 2 recurrent pericarditis study, shifting the expected topline data release to Q1 2026 to allow for dose-ranging evaluations and expansion into Canada, the EU, and the UK [5] - The ongoing study continues to focus on evaluating safety, pain reduction, and inflammatory markers, with extended follow-up planned for eligible patients [5] Group 4: Stock Performance - Ventyx shares declined 15.35% from the prior close of $9.38, ending at $7.94, with a 10% drop earlier in the day due to investor reactions to the delayed interim data [6] - The company develops oral small-molecule therapies for autoimmune, inflammatory, and neurodegenerative diseases, with multiple Phase 2 programs targeting NLRP3, TYK2, and S1P pathways [6]